Treatment of B-cell Prolymphocytic Leukemia with Normal TP53 (No Deletion or Mutation)

Clinical scenario

This protocol addresses patients with B-cell prolymphocytic leukemia (B-PLL) whose TP53 status is intact — specifically, no TP53 gene deletion and no TP53 mutation. This subset represents approximately half of B-PLL cases and carries a distinct therapeutic profile compared to TP53-aberrant disease.

TP53 status and treatment strategy

For B-PLL with normal TP53, a conventional chemo-immunotherapy approach is considered reasonable. For patients with TP53 deletion or mutation, a different strategy applies — this protocol is specific to those without such alterations. TP53 testing is therefore a critical step in determining the appropriate treatment path.

Treatment approach (partial)

For eligible patients with B-PLL and normal TP53 who achieve first remission, consolidation with a potentially curative transplantation strategy may be considered — the full structured regimen specifies eligibility criteria and sequencing.

Full regimen, sequencing, and eligibility details available via the protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/asheducation-2015.1.361

However, for the 50% of cases with normal TP53, a conventional chemo-immunotherapy approach with FCR or bendamustine and rituximab is reasonable.

For T-PLL, first-line therapy is with intravenous alemtuzumab and for B-PLL is with combination chemo-immunotherapy for patients with normal TP53 and with alemtuzumab or BCR inhibitors for those with deletions or mutations of TP53.

For these reasons, it is appropriate to consider potentially curative treatment with allogenic SCT in first remission for eligible patients.

For this reason, suitable patients may be considered for early allogenic SCT, as in T-PLL.

View source ↗